STOK (Stoke Corp) Gross Profit Margin

Official company branding of Stoke Therapeutics Inc (STOK)

Stoke Therapeutics focuses on restoring protein balance in genetic pathologies of the eyes and brain. Production margins demonstrate current yield dynamics, where the 84.60 level indicates the state of the parameter. The development of epilepsy therapy is currently in the testing phase prior to the start of sales, while strategic alliances with pharma behemoths are accelerating the implementation of innovative DNA technologies.

Stoke Corp (STOK) Return on Gross Profit: for the period 07/04/2022 - 11/20/2026

Financial and market metric breakdowns for stoketherapeutics.com (STOK)

Basic company analysis:STOK - Stoke Therapeutics Inc
Mass-produced product of Stoke Therapeutics

For RNA medicine pioneer Stoke Therapeutics, which is implementing protein synthesis stimulation technology, absolute gross margin reflects the efficiency of managing direct development costs. The current value of 84.60 demonstrates the share of revenue net of cost of goods sold, where an increase in this metric signals the optimization of production processes and enhanced fundamental business resilience during the scaling of innovative therapy.

Main competitors

Return on Gross Profit Tempus AI Inc|QGEN (Qiagen NV) - Gross Margin|Return on Gross Profit Ionis Pharma (IONS)|Gross Profitability Repligen Corp (RGEN)|RNA - Gross Profit Margin|crisprtx.com - Return on Gross Profit|Gross Profit Rate WGS|RARE - Gross Profitability|Beam Tx (BEAM) - Return on Gross Profit|SRPT (Sarepta Therapeutics Inc) - Return on Gross Profit|TWST: Gross Profit Ratio|TXG (10xgenomics.com) - Gross Margin|NTLA (Intellia Therapeutics, Inc.) - Gross Profit Ratio|Gross Margin BLFS|Gross Profitability WVE (Wave Life Sciences Corp)|Gross Profitability Maze Therapeutics MAZE|Gross Profit Rate SION|PRME - Gross Profitability|Return on Sales by Gross Profit Taysha TSHA|QURE: Gross Margin|Return on Gross Profit MeiraGTx PLC|RGNX (REGENXBIO Inc) - Gross Margin|solidbio.com (SLDB) - Return on Sales by Gross Profit|Gross Profitability Ocugen Corp (OCGN)|Pacific Biosciences of California, Inc. - Gross Return on Sales|Benitec Biopharma - Return on Gross Profit|DSGN: Gross Return on Sales|RCKT: Return on Gross Profit|FDMT - Gross Margin|LXEO: Gross Margin|Korro Bio Inc. - Gross Profit Rate|EDIT (editasmedicine.com) - Gross Margin|Gross Profitability SLN|Gross Profitability ProQR Therapeutics NV (PRQR)|Codexis - Gross Return on Sales|Gross Profitability Sangamo SGMO|NAUT: Gross Return on Sales|MGX: Return on Gross Profit|Gross Profit Margin Precision BioSciences|GBIO (generationbio.com) - Return on Gross Profit|Gross Profit Margin boundlessbio.com (BOLD)|XCUR (exicuretx.com) - Gross Margin|Gross Return on Sales IMNN (Imunon, Inc.)|Gross Margin PHIO|MBIO - Gross Profit Margin|Gross Margin RNAZ (TransCode Therapeutics)|bionanogenomics.com (BNGO) - Gross Profit Margin|Applied DNA - Gross Margin|Gross Profit Margin Bluebird Bio|ImmunoPrecise (IPA) - Gross Profitability|Gross Profitability Margin OMGA (Omega)|Gross Profitability Singular Genomics Systems|Gross Profit Margin regulusrx.com RGLS|Gross Profitability Syros Pharmaceuticals Inc. (SYRS)|Return on Sales by Gross Profit Codex DNA|Gross Profitability TRACON TCON|Unity Biotechnology, Inc - Gross Profitability